What This Means
This research suggests that multiple myeloma, a type of blood cancer, has been growing much faster in China than in the rest of the world over the past 33 years. In China, the rate of new cases more than tripled between 1990 and 2023, while globally the increase was far more modest. The same faster-than-global growth was seen not just in new cases, but also in how many people are living with the disease, how many die from it, and the overall years of healthy life lost due to the illness. Currently, men in China are more affected than women, and older people carry a disproportionately higher burden.
Looking ahead to 2050, the study's mathematical models project a notable shift: in China, the rate of new cases among women may actually overtake the rate among men, suggesting women will bear an increasingly large share of the disease burden. Globally, cases are expected to keep rising for both men and women, but without this kind of sex reversal. These projections were made using a sophisticated statistical approach called Bayesian age-period-cohort modeling, which accounts for how age, time period, and birth cohort all influence disease trends.
This research suggests that China faces a growing and distinctive multiple myeloma challenge that differs meaningfully from global patterns. The rapid rise in cases, especially the projected surge among women, points to an urgent need for China to strengthen public health strategies focused on early detection, treatment access, and prevention research tailored to its specific population dynamics.